Larimar Therapeutics, Inc. (DE:ZA71)

NASDAQ:ZA71

ZA71

Larimar Therapeutics

RESEARCH TOOLSreports

Larimar Therapeutics (ZA71) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZA71 Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Larimar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZA71 Stock 12 Month Forecast

Average Price Target

€12.91

▲(219.64% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Larimar Therapeutics in the last 3 months. The average price target is €12.91 with a high forecast of €21.52 and a low forecast of €7.75. The average price target represents a 219.64% change from the last price of €4.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","11":"€11","22":"€22","5.5":"€5.5","16.5":"€16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.522427750000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€21.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.91345665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.74807399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.5,11,16.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,4.424802134615385,5.8496042692307695,7.274406403846154,8.699208538461539,10.124010673076924,11.548812807692308,12.973614942307693,14.398417076923078,15.823219211538463,17.24802134615385,18.67282348076923,20.097625615384615,{"y":21.522427750000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,3.7625735884615388,4.5251471769230776,5.287720765384615,6.050294353846154,6.812867942307693,7.575441530769231,8.33801511923077,9.100588707692308,9.863162296153847,10.625735884615386,11.388309473076925,12.150883061538462,{"y":12.91345665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3,3.3652364607692307,3.7304729215384613,4.095709382307692,4.460945843076923,4.826182303846154,5.191418764615385,5.556655225384615,5.921891686153846,6.287128146923077,6.6523646076923075,7.017601068461539,7.38283752923077,{"y":7.74807399,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€21.52

Average Price Target€12.91

Lowest Price Target€7.75

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tessa Romero

J.P. Morgan

€7.75

Buy

91.78%

Upside

Initiated

05/27/26

Larimar Therapeutics initiated with an Overweight at JPMorganLarimar Therapeutics initiated with an Overweight at JPMorgan

Myles Minter

William Blair

―

Buy

―

Reiterated

05/18/26

Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics

Laura Chico

Wedbush

€10.33

Buy

155.71%

Upside

Reiterated

05/18/26

Larimar Therapeutics price target lowered to $12 from $13 at WedbushLarimar Therapeutics price target lowered to $12 from $13 at Wedbush

Francois Brisebois

LifeSci Capital

€21.52

Buy

432.73%

Upside

Assigned

05/16/26

Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained

Samantha Semenkow

Citi

€12.05

Buy

198.33%

Upside

Reiterated

03/20/26

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Catherine Novack

JonesTrading

€6.03→€11.19

Buy

177.02%

Upside

Reiterated

02/24/26

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Palvella Therapeutics (NASDAQ: PVLA) and Larimar Therapeutics (NASDAQ: LRMR)

Jonathan Wolleben

Citizens JMP

€15.5

Buy

283.57%

Upside

Reiterated

10/06/25

Larimar Therapeutics (LRMR) Receives a Buy from Citizens JMP

Joel Beatty

Robert W. Baird

€8.61→€6.03

Buy

49.17%

Upside

Reiterated

09/30/25

Larimar Therapeutics price target lowered to $7 from $10 at BairdLarimar Therapeutics price target lowered to $7 from $10 at Baird

Joori Park

Leerink Partners

€21.52

Buy

432.73%

Upside

Reiterated

09/30/25

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

Yatin Suneja

Guggenheim

€22.38

Buy

454.04%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tessa Romero

J.P. Morgan

€7.75

Buy

91.78%

Upside

Initiated

05/27/26

Larimar Therapeutics initiated with an Overweight at JPMorganLarimar Therapeutics initiated with an Overweight at JPMorgan

Myles Minter

William Blair

―

Buy

―

Reiterated

05/18/26

Larimar Therapeutics: Buy Rating Backed by Superior Nomlabofusp Data and Favorable Risk-Reward Versus Design Therapeutics

Laura Chico

Wedbush

€10.33

Buy

155.71%

Upside

Reiterated

05/18/26

Larimar Therapeutics price target lowered to $12 from $13 at WedbushLarimar Therapeutics price target lowered to $12 from $13 at Wedbush

Francois Brisebois

LifeSci Capital

€21.52

Buy

432.73%

Upside

Assigned

05/16/26

Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained

Samantha Semenkow

Citi

€12.05

Buy

198.33%

Upside

Reiterated

03/20/26

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

Catherine Novack

JonesTrading

€6.03→€11.19

Buy

177.02%

Upside

Reiterated

02/24/26

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Radnet (NASDAQ: RDNT), Palvella Therapeutics (NASDAQ: PVLA) and Larimar Therapeutics (NASDAQ: LRMR)

Jonathan Wolleben

Citizens JMP

€15.5

Buy

283.57%

Upside

Reiterated

10/06/25

Larimar Therapeutics (LRMR) Receives a Buy from Citizens JMP

Joel Beatty

Robert W. Baird

€8.61→€6.03

Buy

49.17%

Upside

Reiterated

09/30/25

Larimar Therapeutics price target lowered to $7 from $10 at BairdLarimar Therapeutics price target lowered to $7 from $10 at Baird

Joori Park

Leerink Partners

€21.52

Buy

432.73%

Upside

Reiterated

09/30/25

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

Yatin Suneja

Guggenheim

€22.38

Buy

454.04%

Upside

Reiterated

09/29/25

Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Larimar Therapeutics

3 Months

Jonathan WollebenCitizens JMP

Success Rate

14/23 ratings generated profit

Average Return

+27.03%

Copying Jonathan Wolleben's trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +27.03% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

13/23 ratings generated profit

Average Return

+29.47%

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of +29.47% per trade.

2 Years

Joon LeeTruist Financial

Success Rate

4/8 ratings generated profit

Average Return

+0.09%

Copying Joon Lee's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +0.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZA71 Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZA71 has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ZA71 average Analyst price target in the past 3 months is 12.91.

Each month's total comprises the sum of three months' worth of ratings.

ZA71 Financial Forecast

ZA71 Earnings Forecast

Next quarter’s earnings estimate for ZA71 is -€0.34 with a range of -€0.41 to -€0.27. The previous quarter’s EPS was -€0.27. ZA71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ZA71 has Performed in-line its overall industry.

No data currently available

ZA71 Sales Forecast

Next quarter’s sales forecast for ZA71 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. ZA71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ZA71 has Performed in-line its overall industry.

ZA71 Stock Forecast FAQ

What is DE:ZA71’s average 12-month price target, according to analysts?

Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 12.91.

What is DE:ZA71’s upside potential, based on the analysts’ average price target?

Larimar Therapeutics, Inc. has 219.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Larimar Therapeutics, Inc. a Buy, Sell or Hold?

Larimar Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Larimar Therapeutics, Inc.’s share price target?

The average share price target for Larimar Therapeutics, Inc. is 12.91. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €21.52 ,and the lowest forecast is €7.75. The average share price target represents 219.64% Increase from the current price of €4.04.

What do analysts say about Larimar Therapeutics, Inc.?

Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Larimar Therapeutics, Inc.?

To buy shares of DE:ZA71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Larimar Therapeutics (ZA71) Stock Forecast & Price Target

ZA71 Analyst Ratings

ZA71 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Larimar Therapeutics

ZA71 Analyst Recommendation Trends

ZA71 Financial Forecast

ZA71 Earnings Forecast

ZA71 Sales Forecast

ZA71 Stock Forecast FAQ

Detailed List of Analyst Forecasts